In an important development for rare disease treatment, the U.S. Food and Drug Administration (FDA) has expanded the approval of Juxtapid (lomitapide) capsules for pediatric patients with homozygous familial hypercholesterolemia (HoFH). The decision allows the medication to be used in children aged 2 years and older, providing a new therapeutic option for families facing this extremely rare and life-threatening genetic condition.
The announcement was made by Chiesi Global Rare Diseases during the week of Rare Disease Day. The timing highlights the ongoing effort to raise awareness about rare medical conditions and the challenges experienced by patients and caregivers.
This expanded approval marks a significant milestone in the treatment of HoFH, especially for young children who may develop dangerously high cholesterol levels early in life.
Homozygous familial hypercholesterolemia is an ultra-rare inherited disorder that affects the body’s ability to remove low-density lipoprotein cholesterol, commonly called LDL or “bad cholesterol,” from the bloodstream.
Normally, the body uses LDL receptors to clear excess cholesterol from circulation. However, people with HoFH have severely impaired or absent LDL receptor function due to genetic mutations. As a result, LDL cholesterol builds up rapidly in the blood.
This condition affects an estimated 1 in 250,000 to 1 in 360,000 individuals worldwide, making it one of the rarest forms of high cholesterol.
Children born with HoFH can experience extremely high cholesterol levels from birth. Without treatment, the condition may lead to:
Because of these risks, early diagnosis and treatment are critical.
According to cardiovascular research, individuals with untreated HoFH may develop serious heart disease even during childhood or adolescence. Early intervention can significantly reduce long-term complications.
Juxtapid, also known by its generic name lomitapide, is a prescription medication designed to lower LDL cholesterol in patients with HoFH.
The drug works by inhibiting a protein called microsomal triglyceride transfer protein (MTP). This protein plays a role in the production of lipoproteins in the liver and intestines.
By blocking this process, Juxtapid reduces the amount of cholesterol that enters the bloodstream.
Juxtapid is not used alone. It is typically prescribed alongside:
The medication has been approved for adult patients with HoFH in the United States since 2012. The new FDA decision expands its use to younger patients.
For children with HoFH, treatment options have historically been limited. Many therapies were originally studied only in adults.
The new approval means children as young as two years old may now benefit from a therapy that has already shown effectiveness in adults.
Experts say this change could help reduce the long-term cardiovascular damage associated with the condition.
According to Mitch Goldman, Senior Vice President of Research and Development at Chiesi Global Rare Diseases, expanding the therapy to younger patients represents meaningful progress for families affected by HoFH.
Early treatment can help manage cholesterol levels before severe artery damage occurs.
The FDA’s approval was supported by data from a Phase 3 open label multicenter study known as APH-19.
The trial evaluated the safety and effectiveness of Juxtapid in 43 pediatric patients aged 5 to 17 years who had HoFH.
All participants were already receiving standard cholesterol lowering treatments and following a low fat diet.
Over a 24 week treatment period, Juxtapid doses were gradually adjusted to the highest level each participant could tolerate.
The study produced promising results:
These results showed meaningful improvement in cholesterol control for the pediatric participants.
The safety profile observed in the study was consistent with the known effects of the medication.
Most reported side effects were related to:
Researchers concluded that Juxtapid provided clinically meaningful LDL cholesterol reductions in pediatric patients with HoFH.
Although Juxtapid can be an effective therapy, it carries important safety warnings and must be used under careful medical supervision.
One of the most important safety concerns involves liver health.
Juxtapid can increase liver enzyme levels or cause fat accumulation in the liver. Because of this risk, doctors typically perform regular blood tests before and during treatment.
Patients should immediately report symptoms such as:
Common side effects may include:
Following a strict low-fat diet may help reduce these symptoms.
The medication can also interfere with the absorption of certain nutrients, particularly fat-soluble vitamins like vitamin E.
Doctors often recommend vitamin supplements to help prevent deficiencies.
Juxtapid should not be used during pregnancy because it may harm an unborn baby.
Women who can become pregnant must use effective birth control during treatment and for two weeks after the last dose.
Juxtapid is available only through pharmacies certified under the Juxtapid REMS Program, a risk management system required by the FDA.
Healthcare providers must enroll in this program to prescribe the medication. The program ensures that patients receive proper monitoring and safety information.
In addition, a patient registry collects long term data about the medication’s effects. This helps researchers better understand outcomes over time.
Living with HoFH can place a heavy burden on children and their families.
Frequent medical appointments, strict dietary restrictions, and ongoing monitoring can affect daily life.
Advocacy organizations such as the Family Heart Foundation emphasize the emotional and medical challenges faced by young patients.
For many families, the expansion of Juxtapid treatment represents hope for better long-term health outcomes.
Early treatment could help slow the progression of cardiovascular disease and improve quality of life.
Rare diseases affect millions of people globally, even though each individual condition may impact only a small number of patients.
Research and drug development in this area have historically faced challenges including:
However, increased attention from regulatory agencies and pharmaceutical companies has led to more treatments for rare conditions.
The FDA has implemented programs designed to encourage the development of therapies for rare diseases, including orphan drug designation and accelerated approval pathways.
Chiesi Global Rare Diseases is a specialized division of the Chiesi Group that focuses on therapies for rare and ultra-rare medical conditions.
The company is part of a broader international biopharmaceutical organization headquartered in Parma, Italy.
Chiesi has more than 90 years of experience in developing treatments across several therapeutic areas, including respiratory medicine and specialty care.
The company operates in more than 30 countries and employs over 7,500 people worldwide.
Chiesi is also certified as a B Corporation, which means it meets strict standards related to social and environmental impact.
The expanded approval of Juxtapid for pediatric patients represents progress in addressing one of the most severe inherited cholesterol disorders.
While HoFH remains a challenging condition to manage, earlier access to treatment could help reduce long-term cardiovascular risks.
Researchers continue to explore additional therapies, including gene based treatments and new lipid lowering drugs that may further improve outcomes for patients with this rare disease.
For families affected by HoFH, advancements like this provide an important step toward better care and improved quality of life.
This article is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment plan. Drug safety information may change over time, and individual medical needs vary.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.